XENCOR INC. news, videos and press releases
For more news please use our advanced search feature.
XENCOR INC. - More news...
XENCOR INC. - More news...
- Xencor Reports First Quarter 2025 Financial Results
- Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
- Xencor Appoints Todd Simpson to Board of Directors
- Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
- Xencor to Participate at Upcoming Investor Conferences
- Xencor Reports Second Quarter 2023 Financial Results
- Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
- Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
- Xencor Reports First Quarter 2023 Financial Results
- Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
- Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
- Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
- Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
- Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
- Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
- Xencor to Present at the SVB Securities Global Biopharma Conference
- Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
- Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates
- Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
- Xencor to Present at Upcoming Investor Conferences
- Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
- Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
- Xencor Reports Third Quarter 2022 Financial Results
- Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
- Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
- Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
- Xencor Appoints Nancy Valente, M.D., to Board of Directors
- Xencor Reports Second Quarter 2022 Financial Results
- Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
